Akeso Doses First Patient in HER3 ADC Lung Cancer Trial
Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...
ZURICH, Switzerland – February 27, 2026 Veraxa Biotech AG announced that its shareholders have approved the previously disclosed business...
